Cointime

Kira Biotech

company

About

Kira Biotech is an Immunology Company.

  • 1 - 10

Highlights

Total Funding Amount
$20M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Series A
Last Funding Money Raised
$20M
Industries
Biotechnology
Founded date
Jan 1, 2019
Number Of Employee
1 - 10
Operating Status
Active

Kira Biotech is an emerging Australian biotechnology company developing novel immunomodulatory compounds for the treatment of immune system disorders. Its lead candidate, KB312, is a first-in-class, selective, immune-cell depleting monoclonal antibody which targets activated immune cells and aims to restore homeostasis through induction of immune tolerance. Kira Biotech has attracted venture capital funding and is progressing KB312 through preclinical development and phase 1 clinical trials with a team of drug development experts led by well-known US-based rheumatologist and immunologist, Dr Dan Baker.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$20M
Kira Biotech has raised a total of $20M in funding over 2 rounds. Their latest funding was raised on Oct 28, 2019 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 28, 2019 Series A $20M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
Kira Biotech is funded by 1 investors. Queensland Business Development Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Queensland Business Development Fund — Series A
Cointime
Content
Company